CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 394 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04750330
NCT04750330N/ACompleted

Mitochondrial DNA and Nuclear SNPs to Predict Severity of COVID-19 Infection

Maastricht University·observational·Posted Feb 11, 2021·Updated Jun 15, 2023

In Brief

An observational study for Covid19. Completed, enrolled 394 participants across 3 sites in 3 countries.

Detailed Summary

In December 2019, the first people got infected with COVID-19 in Wuhan, China. Within weeks, this highly infectious disease spread all over the world. Nearly one year later everyone is still trying to battle this disease and facing the consequences it causes. What became clear is that the disease and its severity differs largely between infected people. However, knowledge about who will experience severe COVID-19 and who does not is still unclear. Therefore, the aim of this study is to investigate the prognostic value of certain parameters (mtDNA and CT radiomics signature) for the severity of COVID-19.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesGreece, Italy, Portugal

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedFeb 11, 2021
Enrollment StartApr 1, 2021
Primary CompletionJun 12, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.4 years ago